Safety signals identified through extended follow-up include: Gastrointestinal effects : Nausea, vomiting, and diarrhea remain the most common adverse events, typically diminishing over time but causing discontinuation in approximately 57% of patients Gallbladder disease : Increased incidence of cholelithiasis and cholecystitis, possibly associated with weight loss, though the exact mechanism remains under investigation Diabetic retinopathy : Risk of complications, particularly with rapid glycemic improvement in patients with pre-existing retinopathy Acute kidney injury : Risk associated with severe gastrointestinal adverse events leading to dehydration Pancreatitis : Rare cases reported, though causality remains uncertain
Health care providers are encouraged to report any prenatal exposure to Januvia by calling the Pregnancy Registry at (800) 986-8999
Dosage Information For Semaglutide: Ozempic and Wegovy Nov 14, 2023 2 min read Updated: Feb 6, 2024 Although Ozempic and Wegovy both contain the active ingredient Semaglutide, they are intended for different purposes and so have different dosages to reflect this
ChoCETaesuwanSMalyshevaOVBenderETulchinskyNFYanJet al
How they work together: Metformin increases natural GLP-1 secretion in the gut